CTKB (Cytek Biosciences) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


CTKB Cytek Biosciences Inc CTKB
71 GF Score
Price $4.46
GF Value $5.82
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cytek Biosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cytek Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CTKB vs BBNX, TCMD, NPCE: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Cytek Biosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytek Biosciences Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Margin of Safety % (DCF Earnings Based) falls into.


CTKB
71GF Score
Cytek Biosciences Inc CTKB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Other Exchanges 8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score

Get the complete analysis for CTKB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.46
Price
$5.82
GF Value